Biopharma’s 5 Biggest M&A Deals of 2022

Mergers and acquisitions were widely expected to be a key theme in the biopharmaceutical industry in 2022.

Several big pharma companies were flush with cash leading into the year, thanks to their top-selling COVID-19 products, innovative branded medications and high-value divestitures.

Eleven mega-blockbuster medicines, defined as products generating sales greater than $5 billion per year, are set to lose global patent protection this decade.